Nichols Kristen R, Karmire Lauren C, Cox Elaine G, Kays Michael B, Knoderer Chad A
Butler University College of Pharmacy and Health Sciences, Indianapolis, IN, USA Riley Hospital for Children at IU Health, Indianapolis, IN, USA Indiana University School of Medicine, Indianapolis, IN, USA
Butler University College of Pharmacy and Health Sciences, Indianapolis, IN, USA.
Ann Pharmacother. 2015 Apr;49(4):419-26. doi: 10.1177/1060028014566447. Epub 2015 Jan 22.
Extended-infusion cefepime (EIC) has been associated with decreased mortality in adults, but to our knowledge, there are no studies in children.
The objective of this study was to determine the feasibility of implementing EIC as the standard dosing strategy in a pediatric population.
This was a descriptive study of children aged 1 month to 17 years, including patients in the intensive care unit, who received cefepime after admission to a freestanding, tertiary care children's hospital. Patients were excluded if they were admitted to the neonatal intensive care unit or received cefepime in the outpatient, operating, or emergency department areas. Demographic and clinical data for patients who received cefepime from April through August 2013, the period following EIC implementation, were extracted from the medical records.
A total of 150 patients were included in the study, with a median age (interquartile range [IQR]) of 6 years (2-12.3 years) and median weight (IQR) of 20.7 kg (13.2-42.8 kg); 143 patients received cefepime via extended infusions, and 10 (7.0%) of those were changed to a 30-minute infusion during treatment. The most common reasons for infusion time change were intravenous (IV) incompatibility and IV access concerns, responsible for 50% of changes. Dosing errors and reported incidents during therapy were sparse (n = 12, 8.0%) and were most commonly related to renal dosing errors and/or initial dose error by prescriber.
Because 93.0% of the patients who initially received EIC remained on EIC, implementation of EIC as the standard dosing strategy was feasible in this pediatric hospital.
延长输注时间的头孢吡肟(EIC)与成人死亡率降低相关,但据我们所知,尚无关于儿童的研究。
本研究的目的是确定在儿科人群中将EIC作为标准给药策略实施的可行性。
这是一项对1个月至17岁儿童的描述性研究,包括入住一家独立的三级护理儿童医院后接受头孢吡肟治疗的重症监护病房患者。如果患者入住新生儿重症监护病房或在门诊、手术室或急诊科接受头孢吡肟治疗,则将其排除。从病历中提取2013年4月至8月(EIC实施后的时间段)接受头孢吡肟治疗的患者的人口统计学和临床数据。
共有150名患者纳入研究,中位年龄(四分位间距[IQR])为6岁(2 - 12.3岁),中位体重(IQR)为20.7 kg(13.2 - 42.8 kg);143名患者通过延长输注接受头孢吡肟治疗,其中10名(7.0%)在治疗期间改为30分钟输注。输注时间改变的最常见原因是静脉内(IV)不相容性和静脉通路问题,占改变原因的50%。治疗期间的给药错误和报告事件较少(n = 12,8.0%),最常见的与肾脏给药错误和/或开处方者的初始剂量错误有关。
由于最初接受EIC治疗的患者中有93.0%继续接受EIC治疗,因此在这家儿科医院将EIC作为标准给药策略实施是可行的。